AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 188 filers reported holding AKERO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,226,363 | +62.1% | 24,246 | +22.6% | 0.01% | +80.0% |
Q1 2023 | $756,707 | -88.0% | 19,778 | -82.9% | 0.01% | -86.5% |
Q4 2022 | $6,328,523 | +58.6% | 115,484 | -1.4% | 0.04% | +68.2% |
Q3 2022 | $3,990,000 | +1989.0% | 117,175 | +478.8% | 0.02% | +2100.0% |
Q2 2022 | $191,000 | +69.0% | 20,243 | +154.1% | 0.00% | 0.0% |
Q1 2022 | $113,000 | +205.4% | 7,966 | +356.0% | 0.00% | – |
Q4 2021 | $37,000 | -43.9% | 1,747 | -40.9% | 0.00% | -100.0% |
Q3 2021 | $66,000 | -72.3% | 2,958 | -69.2% | 0.00% | -66.7% |
Q2 2021 | $238,000 | +35.2% | 9,613 | +40.8% | 0.00% | +50.0% |
Q4 2020 | $176,000 | +183.9% | 6,829 | +241.4% | 0.00% | +100.0% |
Q3 2020 | $62,000 | +244.4% | 2,000 | +177.8% | 0.00% | – |
Q2 2020 | $18,000 | -50.0% | 720 | -57.8% | 0.00% | -100.0% |
Q1 2020 | $36,000 | +56.5% | 1,707 | +62.7% | 0.00% | – |
Q4 2019 | $23,000 | -61.0% | 1,049 | -59.7% | 0.00% | -100.0% |
Q3 2019 | $59,000 | -32.2% | 2,603 | -42.9% | 0.00% | -50.0% |
Q2 2019 | $87,000 | – | 4,560 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 5,830,203 | $179,512,000 | 24.20% |
venBio Partners LLC | 2,444,311 | $75,260,000 | 11.44% |
Versant Venture Management, LLC | 777,727 | $23,946,000 | 4.38% |
Redmile Group, LLC | 2,336,357 | $71,936,000 | 1.32% |
Vivo Capital, LLC | 571,833 | $17,607,000 | 1.02% |
Cormorant Asset Management, LP | 859,550 | $26,466,000 | 1.02% |
Boxer Capital, LLC | 831,495 | $25,602,000 | 0.88% |
Integral Health Asset Management, LLC | 85,000 | $2,617,000 | 0.80% |
EAM Global Investors LLC | 49,718 | $1,531,000 | 0.56% |
Crawford Lake Capital Management, LLC | 43,826 | $1,349,000 | 0.56% |